Dupilumab, first approved in early 2017 in the US[1], and subsequently approved in the EU (September 2017) [2] and Canada (December 2017)[3], has now also been approved in Japan.[4]

In late January, 2018 Regeneron announced that Ministry of Health, Labor and Welfare (MHLW) in Japan had authorized manufacturing and marketing of dupilumab, which it is jointly developing under a global collaboration agreement with Sanofi. The MHLW has approved the agent for the treatment of atopic dermatitis in adults not adequately controlled with existing therapies; Sanofi will be responsible for the commercialisation of dupilumab in Japan. [4]

For further information related to the first approval of dupilumab please visit Drugs[5], or to learn more about the overall development of dupilumab across all indications visit AdisInsight.[6]

 

Image credit: Ivelin Radkov / Fotolia

 

Leave a Reply